Abstract
Human immunodeficiency virus type 1 (HIV-1)-specific cytotoxic T lymphocytes (CTL) responses provide an important defense in controlling HIV-1 replication, but they fail to control the progression of AIDS in advanced HIV-1 infection. To uncover the situation of these responses in patients with advanced HIV-1 infection, we assessed HIV-1- specific CTL responses in 20 individuals with advanced HIV-1 infection using 407 overlapping peptides spanning all expressed HIV-1 proteins using a gamma interferon – enzyme-linked immunospot (ELISpot) assay. In comparison to 20 individuals with moderately advanced HIV-1 infection, HIV-1-specific CTL responses were significantly decreased (P=0.044) and less peptides could be recognized (P=0.05) in advanced HIV-1 infection. Weakening of Env-gp120 and Gag-specific CTL responses contributed importantly to the decrease of CTL magnitude (P=0.042 and 0.078, respectively), while Env-gp41-specific CTL responses were relatively stronger during the end-stage of HIV-1 infection (P < 0.001). Nef and Env-gp41 represented the most frequently targeted HIV-1 proteins in advanced HIV-1 infection. The entropy scores of peptides targeted in two groups were not significantly different. Only the breadth and magnitude of Envgp41- specific CTL responses were positively correlated with viral loads in advanced HIV-1 infection (P=0.005 and 0.001, respectively). These findings suggest that progressive HIV-1 infection is associated with a weakening of Env-gp120- and Gag-specific CTL responses, and a simultaneous expansion of Env-gp41-specific CTL which is likely driven by high level viral replication.
Keywords: Advanced HIV-1 infection, cytotoxic T-lymphocyte, cellular immune responses, HIV-1 Env-gp41
Current HIV Research
Title: Relative Dominance of Env-gp41-Specific Cytotoxic T Lymphocytes Responses in HIV-1 Advanced Infection
Volume: 6 Issue: 3
Author(s): Yan Zhuang, Yongtao Sun, Song Zhai, Dedong Huang, Shuguang Zhao, Shaoyang Wang, Wenzhen Kang, Xinhong Li, Bruce D. Walker, Marcus Altfeld and Xu G. Yu
Affiliation:
Keywords: Advanced HIV-1 infection, cytotoxic T-lymphocyte, cellular immune responses, HIV-1 Env-gp41
Abstract: Human immunodeficiency virus type 1 (HIV-1)-specific cytotoxic T lymphocytes (CTL) responses provide an important defense in controlling HIV-1 replication, but they fail to control the progression of AIDS in advanced HIV-1 infection. To uncover the situation of these responses in patients with advanced HIV-1 infection, we assessed HIV-1- specific CTL responses in 20 individuals with advanced HIV-1 infection using 407 overlapping peptides spanning all expressed HIV-1 proteins using a gamma interferon – enzyme-linked immunospot (ELISpot) assay. In comparison to 20 individuals with moderately advanced HIV-1 infection, HIV-1-specific CTL responses were significantly decreased (P=0.044) and less peptides could be recognized (P=0.05) in advanced HIV-1 infection. Weakening of Env-gp120 and Gag-specific CTL responses contributed importantly to the decrease of CTL magnitude (P=0.042 and 0.078, respectively), while Env-gp41-specific CTL responses were relatively stronger during the end-stage of HIV-1 infection (P < 0.001). Nef and Env-gp41 represented the most frequently targeted HIV-1 proteins in advanced HIV-1 infection. The entropy scores of peptides targeted in two groups were not significantly different. Only the breadth and magnitude of Envgp41- specific CTL responses were positively correlated with viral loads in advanced HIV-1 infection (P=0.005 and 0.001, respectively). These findings suggest that progressive HIV-1 infection is associated with a weakening of Env-gp120- and Gag-specific CTL responses, and a simultaneous expansion of Env-gp41-specific CTL which is likely driven by high level viral replication.
Export Options
About this article
Cite this article as:
Zhuang Yan, Sun Yongtao, Zhai Song, Huang Dedong, Zhao Shuguang, Wang Shaoyang, Kang Wenzhen, Li Xinhong, Walker D. Bruce, Altfeld Marcus and Yu G. Xu, Relative Dominance of Env-gp41-Specific Cytotoxic T Lymphocytes Responses in HIV-1 Advanced Infection, Current HIV Research 2008; 6 (3) . https://dx.doi.org/10.2174/157016208784324921
DOI https://dx.doi.org/10.2174/157016208784324921 |
Print ISSN 1570-162X |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4251 |
Call for Papers in Thematic Issues
HIV vaccine development
The development of a safe and effective vaccine that impedes HIV-1 transmission and/or limits the severity of infection remains a public health priority. The HIV-1/AIDS pandemic continues to have a disproportionate impact on vulnerable and under-served communities in the USA and globally. In the USA, minority communities that have relatively ...read more
Lymphomas in people living with HIV (PLWH)
In the era of combined antiretroviral therapy (cART), the incidence of lymphoma among people living with HIV (PLWH) surpassed Kaposi's sarcoma in 2011, becoming the most common AIDS-defining malignancy. The annual incidence rate ranges approximately from 100 to 300 per 100,000 individuals with HIV infection as the population denominator, which ...read more
![](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Antipyretic and Anti-inflammatory Effects of Sanchen Pediatric Antipyretic
Paste
The Natural Products Journal Novel Drug Delivery System for Cancer Management: A Review
Current Cancer Therapy Reviews Nicotinic Acetylcholine Receptor Agonists: A Potential New Class of Analgesics
Current Topics in Medicinal Chemistry The Application of Phage Display in Allergy Research: Characterization of IgE, Identification of Allergens and Development of Novel Therapeutics
Current Pharmaceutical Biotechnology Design, Synthesis and In-vivo Anti-inflammatory Activity of New Celecoxib Analogues as NSAID
Mini-Reviews in Medicinal Chemistry Apoptotic Cell Death in Bronchopulmonary Dysplasia
Current Pediatric Reviews From the Editors Perspective: Rational Approaches for Radical Entities
Current Neurovascular Research Lipoxygenase Inhibitors as Cancer Chemopreventives: Discovery, Recent Developments and Future Perspectives
Current Medicinal Chemistry The Early Bird Catches the Worm – Can Evolution Teach us Lessons in Fighting HIV?
Current HIV Research Novel Delivery Systems for Anti-Allergic Agents: Allergic Disease and Innovative Treatments
Current Drug Delivery Nanotechnology-based Drug Delivery, Metabolism and Toxicity
Current Drug Metabolism Endothelial Progenitor Cells as Potential Drug Targets
Current Drug Targets - Cardiovascular & Hematological Disorders Elevated Levels of Bilirubin and Long-Term Exposure Impair Human Brain Microvascular Endothelial Cell Integrity
Current Neurovascular Research Advances and Challenges in Drug Design of PPARδ Ligands
Current Drug Targets Antiviral Agents for Influenza: Molecular Targets, Concerns of Resistance, and New Treatment Options
Current Drug Targets Cytotoxic Effects and Production of Cytokines Induced by the Endophytic Paenibacillus polymyxa RNC-D In Vitro
Current Pharmaceutical Biotechnology Calcium Metabolism and Oxidative Stress in Bone Fractures: Role of Antioxidants
Current Drug Metabolism Preface
Current Psychopharmacology Regulatory Effects of Macrolides on Bacterial Virulence: Potential Role as Quorum-Sensing Inhibitors
Current Pharmaceutical Design HIV-1-Discordant Couples in Sub-Saharan Africa: Explanations and Implications for High Rates of Discordancy
Current HIV Research